SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma (Q44908024)

7 December 2017

title

SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma (English)

1 reference

7 December 2017

1

Pier Luigi Zinzani

1 reference

7 December 2017

Umberto Vitolo

11

0 references

author name string

Monia Marchetti

2

1 reference

7 December 2017

Atto Billio

3

1 reference

7 December 2017

Giovanni Barosi

4

1 reference

7 December 2017

Angelo Michele Carella

5

1 reference

7 December 2017

Mario Lazzarino

6

1 reference

7 December 2017

Maurizio Martelli

7

1 reference

7 December 2017

Alessandro Rambaldi

8

1 reference

7 December 2017

Luigi Rigacci

9

1 reference

7 December 2017

Corrado Tarella

10

1 reference

7 December 2017

Sante Tura

12

1 reference

7 December 2017

Expert Panel of the Italian Society of Hematology

13

1 reference

7 December 2017

publication date

22 January 2013

1 reference

American Journal of Hematology

7 December 2017

published in

1 reference

7 December 2017

volume

88

1 reference

7 December 2017

issue

3

1 reference

7 December 2017

page(s)

185-192

1 reference

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

7 December 2017

cites work

1 reference

Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010

21 January 2018

1 reference

The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organiza

21 January 2018

1 reference

Utility of FDG-PET scanning in lymphoma by WHO classification

21 January 2018

1 reference

18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading

21 January 2018

1 reference

Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?

21 January 2018

1 reference

Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma

21 January 2018

1 reference

Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma

21 January 2018

1 reference

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).

21 January 2018

1 reference

The utility of FDG-PET for managing patients with malignant lymphoma: analysis of data from a single cancer center

21 January 2018

1 reference

Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma

21 January 2018

1 reference

Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas.

21 January 2018

1 reference

Imaging in follicular NHL.

21 January 2018

1 reference

Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study.

21 January 2018

1 reference

Quantitative PCR of bone marrow BCL2/IgH cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma

21 January 2018

1 reference

BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study

21 January 2018

1 reference

Follicular lymphoma international prognostic index.

21 January 2018

1 reference

Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

21 January 2018

1 reference

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

21 January 2018

1 reference

Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.

21 January 2018

1 reference

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

Autologous Stem Cell Transplantation in Follicular Lymphoma: a Systematic Review and Meta-analysis

21 January 2018

1 reference

Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants

21 January 2018

1 reference

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

21 January 2018

1 reference

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma

21 January 2018

1 reference

Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma

21 January 2018

1 reference

Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium

21 January 2018

1 reference

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule

21 January 2018

1 reference

Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials

21 January 2018

1 reference

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

21 January 2018

1 reference

Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.

21 January 2018

1 reference

Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma

21 January 2018

1 reference

Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.

21 January 2018

1 reference

Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.

21 January 2018

1 reference

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

21 January 2018

1 reference

21 January 2018

1 reference

Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning

21 January 2018

1 reference

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20 B-cell lymphoma: long-term follow-up of a phase 1/2 study

21 January 2018

1 reference

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review

21 January 2018

1 reference

Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma

21 January 2018

1 reference

Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up

21 January 2018

1 reference

Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden

21 January 2018

1 reference

Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma?

21 January 2018

1 reference

A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23372

1 reference

7 December 2017

1 reference